Merck and AstraZeneca's Cancer Drug Wins 3 New Approvals in Japan
On Monday, two big pharmaceutical companies delivered some good news about one of their projects. Merck (NYSE: MRK) and AstraZeneca (NASDAQ: AZN) announced in separate press releases that their cancer drug Lynparza received approval by Japan's pharmaceutical regulator for the treatment of three types of the disease: prostate, ovarian, and pancreatic.
The country's Ministry of Health, Labor, and Welfare approved Lynparza as a maintenance treatment following the administration of first-line chemotherapy in patients with certain types of those cancers.
Image source: Getty Images.
Source Fool.com
